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Background: Patients with type 2 diabetes mellitus present a higher proportion of hypo-responsiveness (HR) to acetylsalicylic acid (ASA) and 
clopidogrel (Clo). Patients with high on-treatment reactivity after percutaneous coronary intervention (PCI) are associated to more cardiovascular 
events in the follow-up. The dual resistance to ASA and Clo seems to be related to the increment of markers of myonecrosis after PCI, but do not exist 
data about if the methods of measurement of point of care are useful to detect the patient with risk of suffering a minor myocardial damage (MMD).
Methods: Patients diabetes with non−ST-segment elevation acute coronary syndrome (NSTE-ACS) who underwent PCI with Xience V stent. After PCI 
the in vitro response to antiplatelet therapy was measured: For the ASA the system VerifyNow® assay Aspirin (VNA) and the PFA-100® (PFA). For the 
clopidogrel : The VerifyNow® assay P2Y12 (VNP2Y12). The answer for the dual treatment was analyzed between two groups: Group A: according the 
answer to VNA and VNP2Y12: Group A1: Sensitive (S) to ASA or Clo. Group A2: HR ASA and Clo. Group B: according the answer to PFA and VNP2Y12. 
Group B1: S to ASA or Clo. Group B2: HR to ASA and Clo. Post-PCI Myocardial Infarction was defined as CK-MB ≥ 3 times the upper limit of normal 
(ULN) and greater than baseline levels. MMD: Troponin T (≥ 3xULN) and CK-MB< 3 ULN.
Results: 124 patients were analyzed. The analysis of each measures was determined such individual as by groups. The predictors associated with 
MMD using a univariate analysis were: Sumatory length of stent (p=0.008), number of stent implanted (p=0.002), the VNP2Y12 (2.5% PRU<235 vs. 
15.5% PRU≥235; p=0.03) and the Group B (6.7% B1 vs. 22.9% B2; p=0.01). In a multivariate analysis, only the group B2 (OR: 4.0; 95% CI: 1.3-
12.8,p= 0.01) was independently associated with the incidence of MMD.
Conclusion: The dual hypo-responsiveness to aspirin and clopidogrel measured by PFA-100® and VerifyNow® assay P2Y12 in patients with 
diabetes mellitus with NSTE-ACS treated with Xience V stent is linked to an increment of the MMD, selecting a subgroup of potential risk.
